Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US-2019192651-A1 · Jun 27, 2019 · US
Epstein-barr virus vaccines
US12005115B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12005115-B2 |
| Application number | US-202016922322-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 7, 2020 |
| Priority date | Oct 11, 2013 |
| Publication date | Jun 11, 2024 |
| Grant date | Jun 11, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.
First claim
Opening claim text (preview).
What is claimed: 1. A nucleic acid molecule encoding a recombinant protein, the recombinant protein comprising at least 25 contiguous amino acids from a monomeric subunit protein capable of self-assembling to form a nanoparticle, joined to at least one immunogenic portion from a first Epstein-Barr Virus (EBV) envelope protein is gp350, wherein the encoded recombinant protein comprises an amino acid sequence at least 80% identical to a sequence selected from the group consisting of SEQ ID NO:71, SEQ ID NO:74, SEQ ID NO:77 and SEQ ID NO:80.
Assignees
Inventors
Classifications
Demonstrated in vivo effect · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Fusion polypeptide · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12005115B2 cover?
- Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to f…
- Who is the assignee on this patent?
- The Usa As Represented By The Secretary Dept Of Health And Human Services, The Us Secretary Of The Department Of Health And Human Services
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).